CLOs on the Move

MCS-Medical Consulting and Solutions

www.mcsequipment.com

 
MCS-Medical Consulting & Solutions is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Molecular Biometrics

Molecular Biometrics is a Chester, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SIGNAL MEDICAL CORP

SIGNAL MEDICAL CORP is a Marysville, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Z-Medica Corporation

Z-Medica, LLC is a privately-held medical device manufacturer based in Wallingford, CT that is focused on the development, sale, and marketing of innovative hemorrhage control products for healthcare providers, military personnel, the law enforcement community, first responders, and consumers around the globe. For over a decade, Z-Medica has helped save lives and improve medical outcomes with a growing portfolio of QuikClot hemostatic products that include Control, 4x4 Hemostatic Dressing, Radial, Interventional, Combat Gauze, Belt Trauma Kit, and Bleeding Control Bag. QuikClot products are manufactured in the United States.

Synoptics

Synoptics was formed in 1985 by three researchers from the University of Cambridge who had developed a `tool box` for the generation of image analysis applications. The business grew quickly with many major companies using Synoptics to help develop imaging solutions across a wide range of applications. With a growing knowledge of CCD camera technology, frame grabbing and image capture techniques the company was able to enhance its skill sets within digital imaging.

GT Medical Technologies

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.